+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Insulin Aspart"

Insulin biosimilars Global Market Report 2024 - Product Thumbnail Image

Insulin biosimilars Global Market Report 2024

  • Report
  • January 2024
  • 200 Pages
  • Global
From
From
Insulin Intelligence Center 2012-2023 - Product Thumbnail Image

Insulin Intelligence Center 2012-2023

  • Report
  • May 2024
  • Global
From
Diabetes Drug Intelligence Center 2012-2023 - Product Thumbnail Image

Diabetes Drug Intelligence Center 2012-2023

  • Report
  • May 2024
  • Global
From
From
From
From
Type 1 Diabetes - Pipeline Insight, 2024 - Product Thumbnail Image

Type 1 Diabetes - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 220 Pages
  • Global
From
Human Insulin Market Forecasts from 2023 to 2028 - Product Thumbnail Image

Human Insulin Market Forecasts from 2023 to 2028

  • Report
  • November 2023
  • 144 Pages
  • Global
From
From
From
From
From
From
Loading Indicator

Insulin Aspart is a fast-acting insulin analog used to treat diabetes mellitus, a metabolic disorder. It is used to control high blood sugar levels in adults and children with type 1 diabetes and adults with type 2 diabetes. Insulin Aspart is a recombinant human insulin analog that is produced by recombinant DNA technology. It is a short-acting insulin that is used to control post-meal blood sugar levels. It is usually taken before meals and can be used in combination with other diabetes medications. Insulin Aspart is part of the Endocrine and Metabolic Disorders Drugs market, which includes medications used to treat endocrine and metabolic disorders such as diabetes, thyroid disorders, and obesity. These drugs are used to control blood sugar levels, regulate hormones, and reduce the risk of complications associated with metabolic disorders. Companies in the Insulin Aspart market include Novo Nordisk, Eli Lilly, Sanofi, and Merck. Show Less Read more